Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

Tue, October 27, 2026 at 1:00 PM UTC 2 min read

Aurinia Pharmaceuticals (AUPH) is set to report its Q3 earnings, with analysts projecting a decline compared to the previous quarter. This anticipated decrease may raise concerns among investors regarding the company's financial health and growth trajectory, particularly as it navigates a competitive landscape in the pharmaceutical industry. Investors will be closely monitoring the results for insights into future performance and strategic direction.

Read full article →

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Wed, September 16, 2026 at 5:13 AM UTC 2 min read

Aurinia Pharmaceuticals (AUPH) reported a significant increase in profits, driven by strong sales of its lupus nephritis treatment, LUPKYNIS. The recent approval of a competing drug in the same therapeutic area could impact AUPH's market share, making it crucial for investors to monitor how the company adapts its strategy in response to increased competition. This development highlights the importance of innovation and market positioning in the pharmaceutical sector.

Read full article →